Bones of contention: marrow-derived cells in myocardial regeneration.
Almost 7 years have passed since the initial publication reporting that bone marrow cells regenerate infarcted myocardium. The subsequent years produced hundreds of investigations that ran the gamut of findings from validation to disproof. Undeterred by the concurrent debate, clinical trials ensued to test the safety and efficacy of bone marrow-derived cell population for autologous therapy in clinical treatment of myocardial disease. In the following conversational exchange, two scientists with distinct perspectives weigh the pros and cons of pursuing bone marrow stem cell therapy and look toward finding a consensus of where the future lies for regenerative medicine and the heart. The conclusion is that the two camps may not be as far apart as it may seem from the rancor in literature and at meetings, and the potential of one day achieving regenerative therapy is indeed a vision that both parties enthusiastically share.
Sussman
Mark A
MA
SDSU Heart Institute and Department of Biology, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, USA. Electronic address: sussman@heart.sdsu.edu.
Murry
Charles E
CE
Departments of Pathology and Bioengineering Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA. Electronic address: murry@u.washington.edu.
D000818:Animals; D001854:Bone Marrow Cells / Q000473:pathology; D006801:Humans; D009203:Myocardial Infarction / Q000473:pathology / Q000628:therapy*; D009206:Myocardium / Q000473:pathology; D012038:Regeneration; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000473:pathology